IDiyas

For the Inventor, By the Inventor

East Brunswick, NJ, United States of America

Anne W Dombrowski

USPTO Granted Patents = 15

Average Co-Inventor Count = 5.6

ph-index = 5

Forward Citations = 50(Granted Patents)


Company Filing History:

goldMedal15 out of 4,770 
 
Merck + Co., Inc.
 patents

Years Active: 1992-2003

Loading Chart...
15 patents (USPTO):Explore Patents
1. 6541515 - HIV integrase inhibitors (2003-04-01),
2. 6436395 - Rosellinia subiculata ATCC 74386 and fungus ATCC 74387 for producing sordarin compounds for fungi control (2002-08-20),
3. 6271402 - HIV integrase inhibitors (2001-08-07),
4. 6245806 - HIV integrase inhibitors (2001-06-12),
5. 5994412 - Bis-aryl ethers, compositions containing such compounds and methods of (1999-11-30),
6. 5945317 - Antiparasitic agents (1999-08-31),
7. 5861375 - Antiprotozoal cyclic tetrapeptides (1999-01-19),
8. 5834260 - Antiparasitic agents (1998-11-10),
9. 5759842 - In vitro HIV integrase inhibitors (1998-06-02),
10. 5620953 - Antiprotozoal cyclic tetrapeptides (1997-04-15),
11. 5614546 - Antiparasitic agents (1997-03-25),
12. 5597806 - Antifungal agents (1997-01-28),
13. 5399582 - Antiparasitic agents (1995-03-21),
14. 5244795 - Processes for preparing cholesterol lowering compounds (1993-09-14),
15. 5151365 - Culture of Asperigillus versicolor and mutants thereof (1992-09-29),

Title: Celebrating the Innovations of Anne W. Dombrowski

Introduction

Anne W. Dombrowski, an accomplished inventor based in East Brunswick, NJ, has made significant contributions to the field of pharmacology and microbiology. With a remarkable portfolio of 15 patents, her work predominantly focuses on innovations related to the treatment and prevention of HIV and other phytopathogenic fungi.

Latest Patents

Among her latest patents are groundbreaking inventions that include HIV integrase inhibitors, which are compounds designed to inhibit HIV integrase and provide methods for the prevention and treatment of HIV infections and AIDS. These patents encompass compounds, their pharmaceutically acceptable salts, and various pharmaceutical compositions, which may be combined with other antivirals, immunomodulators, antibiotics, or vaccines. Additionally, she has disclosed the culture of Cytospora sp. MF 6608 (ATCC PTA-1691) and processes for manufacturing related compounds.

Further, her work on controlling phytopathogenic fungi has led to the development of methods using pure strains of Rosellinia subiculata (ATCC 74386) and fungus (ATCC 74387) to produce sordarin compounds. These innovations outline methods of cultivating each strain in nutrient media and recovering the resulting compound, showcasing her dual focus on both human health and agricultural protection.

Career Highlights

Anne Dombrowski’s professional journey has been marked by her association with Merck & Company, Inc., a leading global healthcare company. Her role in this esteemed organization reflects her dedication to advancing medical science and developing life-saving treatments.

Collaborations

Throughout her career, Dombrowski has collaborated with other esteemed professionals, including Sheo B. Singh and Deborah L. Zink. These collaborations have enhanced her research and development efforts, emphasizing the importance of teamwork in achieving innovative solutions in science.

Conclusion

Anne W. Dombrowski exemplifies innovation in the fields of pharmacology and microbiology. Her extensive patent portfolio and collaborative spirit highlight her ongoing commitment to improving health outcomes and tackling pressing global challenges through cutting-edge research and invention.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…